Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Cropscience Ag

Bayer Schering Pharma Ag

Volkhart Li

Heike Gielen-Haertwig

Karl-Heinz Schlemmer

Jörg Keldenich

Josef Pernerstorfer

Leila Telan

Barbara Albrecht

Hilmar Bischoff

Alexandros Vakalopoulos

Carsten Schmeck

Olaf Weber

Michael Thutewohl

Arnd Voerste

Karl-Heinz Kuck

Klemens Lustig

Marcus Bauser

Peter Helmut Schreier

Christian Aichinger

Martina Wuttke

Heike Gielen-Härtwig

The invention relates to novel heterocyclic derivatives of the general formula (I), processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, and heart failure development.

Heterocyclic derivatives

The present invention relates to substituted chromanol derivatives, to processes for their preparation, to their use on their own or in combination for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.

Substituted chromanol derivatives and their use

The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias and arteriosclerosis.

Chemical compound and its use

The invention relates to novel heterocyclic derivatives of the general formula (I), processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development. 

1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors

The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

Dihydropyridinone derivatives

The invention relates to novel 3,4-dihydropyrimidin-2(1H)-one derivatives having the formula processes for their preparation, and their use in compositions, and in the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

The invention relates to polypeptides from phytopathogenic fungi with the biological activity of an inosine monophosphate dehydrogenase, to nucleic acids encoding them, to the use of the polypeptides and nucleic acids for identifying modulators of the polypeptides, to methods for identifying such modulators, and to the use of these modulators as fungicides.

Polypeptides for identifying fungicidally active compounds

Growing community of inventors

Velbert, Germany

Volkhart Li